Measurement · healthcare · emerging marketsJul 20269 min read353 words

Marketing attribution for startups under 20 people for healthcare and life sciences in emerging markets

How under-20-person startups get marketing attribution live without hiring — the specific version of the playbook designed for constraint. Written for commercial leaders at healthtech, medtech, and life-sciences companies in emerging markets.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in emerging markets. In this market, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint, so the way you install marketing attribution has to be shaped to that reality from day one.

The under-20-person version of marketing attribution is not a diluted enterprise playbook. It is the honest answer to which activities create pipeline with different constraints: no headcount, no politics, and no time to be wrong for long.

Own it personally as a founder or lean-in operator for the first quarter. Hiring a specialist too early replaces context with process.

Pick one channel, one trigger, one message. Two of anything at this stage is too many and none of them will work.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in emerging markets it is compounded by the fact that operating footprint and pricing fit, not brand awareness is what actually gates growth. Marketing attribution is only useful here when it is pointed at both constraints at once.

Instrument attribution model reconciled to closed-won in a spreadsheet if you have to. Legibility beats sophistication under 20 people.

The startup-specific trap is picking a model to defend a budget instead of to learn, usually because a well-meaning advisor points at what worked at their $50m company. Ignore.

Budget rules: whatever you spend on tools, spend the same on the person operating them. Under-tooling is fine; under-humaning is not.

A working marketing attribution function at 15 people is a genuine moat — most competitors of that size do not have one, and the discipline carries forward as the company grows.

Concretely for healthcare and life sciences in emerging markets: the healthcare teams that install this get past procurement instead of dying in it, and the teams that install this early own the category before Western vendors even show up. That is the reason it is worth installing marketing attribution deliberately for this market rather than importing a playbook designed for somewhere else.

marketing attributionmulti-touch attributionself-reported attributionstartup marketing attributionmarketing attribution for early stagemarketing attribution for healthcare and life sciencesmarketing attribution in emerging marketshealthcare and life sciences growth in emerging markets

Frequently asked questions

Measurement · healthcare · emerging markets — answered

Does marketing attribution work for healthcare and life sciences in emerging markets?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint. The healthcare teams that install this get past procurement instead of dying in it.
Can a five-person team run marketing attribution?
Yes, if the founder owns it. The lower headcount, the more concentrated the ownership.
What is the smallest useful marketing attribution setup?
One channel, one trigger, one message, and a spreadsheet tracking attribution model reconciled to closed-won.
Should we hire a specialist for marketing attribution?
Not in the first quarter. Own it personally until the model is proven.
What common advice should startups ignore?
Anything derived from a company more than 10x larger. Constraints differ.
What is the emerging markets-specific pitfall when running marketing attribution for healthcare?
Importing a playbook that was built for another market. In emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint — the install has to reflect that.

Growth Broker editorial

Filed under measurement · healthcare · emerging markets

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call